Enhanced Oncolytic Virus Therapy System

The present invention relates to an advanced oncolytic virus therapy system with improved safety and anticancer effect, leveraging novel HSV-TK fragments and machine learning-based design.

While the original oncolytic virus patent provided a significant breakthrough in cancer treatment, it had limitations in terms of safety and efficacy. The new inventive concept addresses these limitations by introducing additional RNA-binding domains, nuclear localization signals, and chimeric HSV-TK fragments, which enhance the specificity and anticancer effect of the oncolytic virus.

The system comprises a recombinant virus vector encoding an HSV-TK fragment with an additional RNA-binding domain, which increases the specificity of the HSV-TK fragment for cancer cells. Additionally, the system incorporates a nuclear localization signal, which enhances the anticancer effect of the HSV-TK fragment. The inventive concept also includes a chimeric HSV-TK fragment with a viral protein, exhibiting improved safety and anticancer effect. Furthermore, the system enables personalized oncolytic virus therapy by selecting an optimal HSV-TK fragment for a patient based on their genetic profile. The inventive concept leverages machine learning algorithms to design HSV-TK fragments with improved safety and anticancer effect, predicting the efficacy of the HSV-TK fragment based on its amino acid sequence.

The new inventive concept introduces several novel elements, including the use of additional RNA-binding domains, nuclear localization signals, and chimeric HSV-TK fragments, which are not present in the original patent. The integration of machine learning algorithms to design HSV-TK fragments with improved safety and anticancer effect is also a significant innovation.

Alternative embodiments of the inventive concept could include the use of different viral vectors, such as adenovirus or lentivirus, or the incorporation of additional therapeutic payloads, such as immunomodulatory molecules or chemotherapeutic agents. Variations of the system could also include the use of different machine learning algorithms or the integration of additional data sources, such as genomic or proteomic data, to improve the design of HSV-TK fragments.

The enhanced oncolytic virus therapy system has significant commercial potential in the cancer treatment market, with potential applications in personalized medicine and targeted therapy. The system could be used to treat a variety of cancer types, including solid tumors and hematological malignancies, and could be marketed to pharmaceutical companies, biotechnology firms, and research institutions.